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Summary
Carcinomas of the biliary tract are rare cancers developing from the
epithelial or blast-like cells lining the bile ducts. A variety of known
predisposing factors and recent experimental models of biliary
carcinogenesis (e.g., infection with the liver fluke Opisthorchis
viverrini, models of chemically induced carcinogenesis and
experimental models of pancreaticobiliary maljunction) have
elucidated different stages of this complex system of biliary
tumorigenesis. Chronic inflammatory processes, generation of
active oxygen radicals, altered cellular detoxification mechanisms,
activation of oncogenes, functional loss of tumor-suppressor genes
and dysregulation of cell proliferation and cell apoptotic
mechanisms have been identified as important contributors in the
development of cholangiocarcinomas. In this review, the known
mechanisms involved in the carcinogenesis of biliary epithelium are
addressed. We will divide the topic into four stages: 1)
Predisposition and risk factors of biliary cancer. 2) Genotoxic
events and alterations leading to specific DNA damage and
mutation patterns. 3) Dysregulation of DNA repair mechanisms and
apoptosis, permitting survival of mutated cells and 4)
Morphological evolution from premalignant biliary lesions to
cholangiocarcinoma. Finally, established and hypothetical future
therapeutic strategies directed towards specific pathogenetic events
during biliary carcinogenesis will be addressed.
Key words: apoptosis, biliary carcinogenesis, cholangiocarcinoma,
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Introduction
Carcinomas of the biliary tract arise from either bile duct
epithelial (oval) cells termed cholangiocytes or non-epithelial
blast-like cells distributed among the oval/bile ductule
epithelial cells. Cholangiocarcinoma (CC) represents a
relatively rare cancer and its prevalence in autopsy series is
reported as 0.01%-0.5% [1]. Despite its rarity, a variety of
predisposing factors have been identified in epidemiological
and clinical series during the past decades. Consequently,
various biliary cancer models were established, that
investigate the initiating mechanisms involved in biliary
carcinogenesis. Such experimental and clinical tumor models
are the liver fluke infection with Opisthorchis viverrini (OV)
[2-4], models of anomalous arrangement of the
pancreaticobiliary ducts (APBD) and bilioenterostomy [5,6],
clinical series of patients with congenital bile duct cysts
(CBDC) and pancreaticobiliary maljunctions (PBM) [7-9]
and tumor induction models that use chemical hepatobiliary
carcinogens such as N-nitrosobis(2-oxopropyl)amine (BOP)
[6,10] or diethylnitrosamine (DEN) [11]. With the
introduction of translational research methods (e.g.
polymerase chain reaction (PCR)), a number of oncogenes,
tumor-suppressor genes and apoptotic proteins involved in
biliary carcinogenesis have been identified [12-14]. Finally,
histomorphological studies have provided some evidence,
that at least in the gallbladder [15,16] and ampulla of Vater
the sequence "intestinal metaplasia-dysplasia-carcinoma" is
significant in biliary carcinogenesis [17]. However, despite
the recent insights into the mechanisms involved in biliary
carcinogenesis, the key events and specific links in this
multi-stage cascade leading to transformation of
cholangiocytes into malignant cells remain unknown and will
need further investigations.
Stage I: Predisposition to biliary carcinogenesis
Table 1 summarizes the identified risk-factors of biliary
carcinogenesis and for some of the predisposing conditions,
the relative risk to develop CC compared to the general
population has been estimated (Table 1). The common
denominator for biliary metaplasia, dysplastic epithelial
transformation, and epithelial proliferation seems to be
chronic inflammation through chemical and/or mechanical
irritation and cholestasis with activation of injurious
pancreatico-biliary compounds and carcinogens.
Anatomic Anomalies:
Congenital bile duct cysts (CBDC), pancreaticobiliary
maljunction (PBM) and Caroli's disease have been clearly
identified to be precursors of biliary cancer. It has been
suggested, that there is an etiological link between congenital
bile duct cyst formation and PBM, since several clinical
series report coincidence of these two conditions in over
90% of cases [8,18]. In CBDC with PBM chronic exposure
of the biliary epithelium to a regurgitated mixture of bile and
pancreatic juice is due to an impaired sphincter of Oddi
function and induces chronic inflammation. In comparison
to normal bile, an elevated amylase level, preactivation of
trypsin, phospholipase A2 and elastase I, and deconjugated
secondary bile acids (e.g. lithocholic acid, deoxycholic acid)
are found in the bile of patients with CBDC and PBM
[8,9,19,20]. Retention of these injurious and comutagenic
substances in the dilated bile duct and/or gallbladder seems
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Table 1. Predisposition to biliary carcinogenesis and relative risk (rR) to
develop cholangiocarcinoma compared to the general population
1.
2.
3.
4.
5.
Anatomic Anomalies:
Chronic inflammatory
conditions:
Biliary calculi
Carcinogens:
Autoimmune diseases:
Predisposition
- Congenital bile duct cysts
- Caroli's disease
-PBM
-PSC
- Typhoid carriers (gallbladder)
- Porcelain gallbladder
- Parasites:
- Opisthorchis vivenini (OV)
- Clonorchis sinensis (CS)5x
- Cholecystolithiasis
- Hepatolithiasis
- Nitrosamines (BOP, DEN)
- Thorotrast
- Betel nut
-PSC
-PBC
-cue
rR
86x
NA
32x
30x
6x
25x
5x
NA
NA
NA
3O3x
NA
30x
30x
75x
Abbreviations: rR - relative risk; NA - not available; PBM -
pancreaticobiliary maljunction; PSC - primary sclerosing cholangitits; BOP
- N-nitrosobis(2-oxopropyl)amine; DEN - diethylnitrosamine; PBC -
primary biliary cirrhosis; CUC - chronic ulcerative colitis
to initiate proliferative epithelial processes with possible
activation of the carcinogenic cascade.
Chronic inflammatory conditions
Primary sclerosing cholangitis (PSC) is the most important
risk-factor for CC in the Western countries. In autopsy
studies CC is present in 33%-42% of patients with PSC [21].
In a series of 30 patients by Rosen and colleagues the
diagnosis of PSC preceded diagnosis of CC by a mean of 52
months [21]. Since PSC mostly develops in patients with
chronic ulcerative colitis (CUC), similar mechanisms for
carcinogenesis of bile duct cancer in PSC and colon cancer
in CUC have been assumed. In fact, identical K-ras gene
point mutations were found in the biliary and colonic
epithelial tumor cells of these patients.
Chronic cholangitis, the chronic infected gallbladder of
typhoid carriers and the porcelain gallbladder (calcification
of the gallbladder) represent endpoints of sustained chronic
inflammation and all these conditions have an elevated risk
of developing CC.
Parasites
The association between CC and the presence of liver flukes
(Opisthorchis viverrini (OV) and Clonorchis sinensis (CS))
has been very well established [2,4]. Infection is acquired by
eating raw or undercooked cypriniod fish contaminated with
encysted metacercariae of the parasites. The flukes
chronically infect the intrahepatic bile ducts, the gallbladder
as well as the pancreatic duct. It has been suggested, that the
parasite infestation by itself is not strongly carcinogenic but
exerts a marked promoting influence on cholangiocellular
tumor development via chronic irritation and increased cell
turnover, rendering the cells susceptible to either exogenous
or endogenous carcinogens [3]. Furthermore, Haswell-Elkins
[2] and Oshima [4] have shown among others, that OV-
infected subjects, as identified by the presence of OV eggs
in the feces, had increased biosynthesis of nitrosamines and
increased nitrosation potential of macrophages compared to
uninfected subjects. Their data supports the hypothesis that
infection with OV increases the generation of genotoxic
nitric oxide (NO), as estimated by elevated salivary nitrite
and urinary nitrate levels in infected subjects [2,4].
Biliary calculi
Gallstones are found in 70-98% of gallbladders resected for
carcinoma [22]. The hypothetical link between gallstones
and carcinoma of the gallbladder relates to the chronic
mechanical irritation and inflammation of the biliary
epithelium. A recent investigation by Ekblom and colleagues
concluded, that gallstones may also play a causative role in
the development of extrahepatic bile duct cancer, since a
significant decrease in the incidence of cholangiocarcinoma
10 or more years after cholecystectomy for
cholecystolithiasis was shown [23]. In analogy to
cholecystolithiasis, hepatolithiasis, which is not uncommon
in East Asia, has been observed in an impressive proportion
(up to 17.5%) of registered cases of CC in these countries
[24]. The liver containing intraductal hepatoliths (mostly
calcium- bilirubinate) show features of chronic proliferative
cholangitis in vicinity to stone-bearing ducts [25].
Carcinogens:
Nitrosamines are potent carcinogens experimentally
inducing tumors in different organs and are suspected to play
a role in human carcinogenesis. Exposure occurs through
dietary intake of preformed nitrosamines, through tobacco
use and through endogenous nitrosation of nitrogenous
compounds via nitric oxide (NO) [4]. However, in vivo little
is known about the carcinogenic concentration and the time
of exposure necessary to induce biliary cancer.
Thorotrast, a radioactive a-particle emitter, was widely used
as a radiocontrast medium between 1930 and 1955. 10-12
years after exposition, liver cancer and cholangiocarcinoma
developed in a large number of Thorotrast treated patients.
Proliferative and dysplastic changes of the bile duct
epithelium were noted in the noncancerous areas of
Thorotrast-induced cholangiocarcinomas which possibly
represent precursor lesions of these cancers [26].
Autoimmune diseases:
Three autoimmune diseases, primary biliary cirrhosis (PBC),
PSC and CUC, have been identified as predisposing
conditions in the development of CC. As mentioned above,
PSC and CUC are often linked, since 75%-83% of patients
with PSC have evidence of CUC. The lifetime risk to
develop CC in patients with CUC was estimated to be 1.4%
[27]. Total proctocolectomy does not protect against the
development of CC which usually appears 15-20 years after
the onset of CUC.
Stage II: Genotoxic cellular events
Genotoxic cellular events which may play an important role
in biliary carcinogenesis have been summarized in Figure 1.
Almost all predisposing factors present with the common
features of chronic inflammation and/or cholestasis. The
resident inflammatory cells are possibly involved in this
carcinogenic process. Cytokines, namely TNF-a and
Interleukin-X (JL-X), ait produced by activated macrophages,
Kupffer cells and hepatocytes during inflammation.
Macrophages activated by such cytokines produce nitric
oxide (NO) and its derivatives, which have been shown to
induce cytotoxic and mutagenic effects in target cells when
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present in excess [4]. NO which has a double-edged role as
an essential physiological signaling and a cytotoxic molecule
reacts rapidly with superoxide anion and decomposes to the
highly reactive and toxic hydroxyl radical (HO) and nitrogen
dioxide (NO2)[28]. It has been demonstrated that NO and its
derivatives can induce DNA damage by deaminating DNA-
nucleobases causing DNA strand breaks [29]. In addition,
excessive NO production has been reported to be
immunosuppressive in vitro, inhibiting lymphocyte
proliferation [30].
Cellular detoxification is an important defensive mechanism
against chemically induced carcinogenesis. UDP-
glucoronosyltransferases (UGT) and glutathione (GSH) were
specifically identified to provide the principal intracellular
Inflammatory states and cholestasis
Reactive Altered Modulation of
compounds Detoxification gene expression
I I I
GSH pathway Activation of
UGT regulation carcinogenOH"
DNA damage
c-myc
K-ras, c-erb-B-2
p53
metabolism
proto-oncogenes and tumor suppressor genes, enhancing cell
proliferation and/or inhibiting cell apoptosis. Over the past
few years, specific mutation spectra of the growth promoting
c-myc, K-ras and c-erb-B-2 oncogenes were identified in the
majority of CC. The prevalence of K-ras mutations in CC is
approximately 80%-100% and CC together with pancreatic
cancer has the highest prevalence of such mutations
[13,33,34]. K-ras point mutations have been localized in
codon 12 with replacement of glycine (GGT) with aspartic
acid (GAT) in most cases [13]. Proto-oncogene activity is
necessary for mediating cell-cycle progression. Point
mutations in specific domaines of this gene family result in
uncontrolled stimulation and signal transduction endowing
the cells with a selective growth advantage [35]. On the side
of apoptosis, loss of function of p53, a tumor suppressor
gene, has been identified to occur in the later stage of
nuclear tumor pathogenesis. Allelic loss or point mutations
of codon 17p, which contains the tumor supressor gene p53,
has been demonstrated in approximately 40% of CC [36,37].
p53 encodes a 53 kd nuclear phosphoprotein that initiates
cell cycle arrest or cell apoptosis, if excessive DNA damage
has occured [38]. A second important function of p53 is
suppression of bcl-2 gene expression, an important gene
involved in the key mechanisms of cell death regulation
through apoptosis [39].
Stage III: Dysregulation of DNA-repair and apoptosis
leading to malignant transformation
Usually genotoxic events with DNA damage lead to either
DNA-mismatch repair mechanisms or, if the damage is
beyond repair, to cell death through apoptosis. Several
proteases have been implicated in apoptosis, including
members of the caspase (ICE) family [40]. Apoptosis is
highly regulated by a growing number of members of the
Bcl-2 family of proteins that block caspase activity [39].
These proteins are localized predominantly at the nucleolus
membrane, endoplasmatic reticulum and mitochondrial
membranes. As mentioned above, loss of p53 function is
followed by overexpression of Bcl-2. This overexpression
contributes to the neoplastic expansion by prolonging cell
survival and failure of apoptosis. Thus, as schematically
drawn in Figure 2, overexpression of Bcl-2 and point
Figure 1. Proposed scheme of genotoxic events in the multistage process of
biliary carcinogenesis
metabolic line of defense in eliminating hydrophobic and
carcinogenic compounds [31,32]. Bioactivation of lipophilic
compounds by cytochrome P-450S can result in the
generation of reactive oxygen compounds. Conjugation with
glucuronic acid by UGTs enables their elimination as
hydrophilic conjugates. In human cholangiocarcinoma down-
regulation of UGT1A4 and UGT1A10 has been
demonstrated to be an early marker of biliary carcinogenesis
[31]. GSH, which is secreted by hepatocytes into bile,
maintains molecules in the reduced state, and similar to
UGT, also participates in the detoxification of different
carcinogenic molecules [32]. The inability to remove
damaging cellular carcinogens predisposes cells to genetic
alterations which can be followed by point-mutations of
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Figure 2. Dysregulation of DNA repair and apoptosis leading to survival of
mutated cells progressing to cholangiocarcinoma (according to Celli et al.
[39]).
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mutations of p53 and K-ras may inhibit apoptosis of DNA
damaged cholangiocytes, permitting survival of the mutated
cell line with progress to CC [39].
Stage FV: Histomorphological aspects in biliary
carcinogenesis
It has been suggested, that similar to colon and stomach
cancer, cholangiocarcinoma arises fromprecancerous lesions
in the biliary tract following the "intestinal metaplasia-
dysplasia-carcinoma" sequence. At least for the gallbladder
and papilla of Vater this hypothesis has been proven [15,16].
As a consequence gallbladder cancers present macro-
scopically more often as flat than as polypoid tumors [41].
Besides this sequence, "de novo" malignant epithelial
transformation as well as cancer formation through adenoma
has been suggested to play a role in histomorphological
cancer development. Kozuka et al. [42] showed in a series of
l'6O5 cholecystectomies that the transition of benign
adenoma to carcinoma is histologically traceable. The same
authors [43] performed histological analysis of 22 invasive
carcinomas of the papilla of Vater finding a rate of 82% of
vestigial adenomas. The retrospective analysis of our own
case material confirms both hypothesis [44]. The surgical
specimens of fifty-eight patients with cancer of the ampulla
of Vater were examined histologically for dysplastic changes
and the incidence of adenomatous structures (Table 2). We
found in 100% of the examined specimens epithelial
dysplasia in the non-carcinomatous part of the ampulla,
82.8% of these being moderate to severe. In 91.4%
adenomatous residues and adenomas were found, implicating
that dysplasia and adenomas are developmental stages in the
neoplastic transformation of the biliary epithelium and
should be considered as pre-cancerous lesions. However, in
some cases of carcinoma of the ampulla of Vater it remains
uncertain which epithelium gave rise to the tumor and
differentiation of bile duct cancer from tumors arising from
the duodenal mucosa may be impossible.
Table 2: Histomorphological alterations of the non-tumor-infiltrated
ampulla in the immediate vicinity of the carcinoma (n=58)
Epithelial dysplasia
stage
Micro-
adenomas
of the mucosa,
%
Macro-
adenomas
and
adenomatous
residues, %
I
n
m
17.2
44.9
37.9
58.6 32.8
Total: 100 adenoma structures 91.4
Therapeutic strategies
Because of the lack of characteristic symptoms and physical
findings, benign biliary tumors and preneoplastic lesions are
usually not diagnosed preoperati vely. Nevertheless, there are
some medical and surgical strategies which may be of some
help in treating CC and decreasing its incidence.
Primary prevention of CC is available by the use of the drug
Praziquantel in high-risk populations with a high prevalence
of liver fluke infestation. Administered in a single dose it
eliminates the parasites successfully from infested
individuals.
Surgical and/or endoscopic removal of precancerous lesions
is mandatory to prevent further progression into CC. Early
surgical resection of choledochal cysts in patients with
CBDC as well as complete excision of the extrahepatic
biliary tract followed by reconstruction and biliopancreatic
separation in patients with PBM may further decrease the
incidence of biliary cancer and result in better survival, since
prognosis of CC is still poor, even after extended resection
[45]. After the onset of CC or gallbladder cancer the
therapeutic strategies are very limitated. Only extended
surgical resectional procedures may offer a chance for cure.
Vitamin C and other antioxidants may be effective in high-
risk patients by interacting with the NO synthase, thus
decreasing endogenous nitrosation and formation of reactive
derivatives. Antioxidants may also decrease oxidative stress-
induced apoptosis.
Attempts are underway to develop new procedures for
targeting the ras protein oncogene products and mutated p53-
associated signal transduction pathways [36], thus
interacting with unregulated cell proliferation and apoptosis.
In the future, CC may be tested for oncogene and tumor
supressor gene targeted therapy. New approaches with Bcl-2
phosphorylators and antisense oligonucleotides targeted
against Bcl-2 are investigated. They may increase tumor cell
susceptibility to chemotherapeutic agents [36,46].
Therefore, the primary goal of therapeutic strategies has to
be the disconnection of the pathogenetic cascade which leads
to the development of CC.
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